TransMedics Group - TMDX Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.

7 brokers have issued 1 year target prices for TransMedics Group's stock. Their TMDX share price forecasts range from $45.00 to $85.00. On average, they anticipate the company's share price to reach $71.57 in the next year. This suggests that the stock has a possible downside of 4.6%.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.

TransMedics Group's stock was trading at $61.72 on January 1st, 2023. Since then, TMDX shares have increased by 21.6% and is now trading at $75.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our TMDX earnings forecast.

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Wednesday, February, 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. The firm earned $31.38 million during the quarter, compared to analyst estimates of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative trailing twelve-month return on equity of 29.82%. The firm's quarterly revenue was up 224.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.46) EPS.

ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), Changebridge Capital Long/Short Equity ETF (CBLS), Changebridge Capital Sustainable Equity ETF (CBSE), SPDR S&P Health Care Equipment ETF (XHE), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Principal Healthcare Innovators ETF (BTEC).

TransMedics Group issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $134.71 million.

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (6.10%), Sandhill Capital Partners LLC (3.77%), Lord Abbett & CO. LLC (3.72%), Driehaus Capital Management LLC (3.45%), Credit Suisse AG (3.25%) and Summit Partners Public Asset Management LLC (3.00%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $75.04.

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.42 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

The company employs 148 workers across the globe.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.